Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation
L Yang, MM Brooks, NW Glynn, Y Zhang, S Saba, I Hernandez
The American Journal of Cardiology | Elsevier | Published : 2020
It remains unknown whether the comparative effectiveness of direct oral anticoagulants (DOACs) and warfarin differs between atrial fibrillation patients with and without a history of stroke or transient ischemic attack (TIA). Using 2012 to 2014 Medicare claims data, we identified patients newly diagnosed with AF in 2013 to 2014 who initiated apixaban, dabigatran, rivaroxaban, or warfarin. We categorized patients based on a history of stroke or TIA. We constructed Cox proportional hazard models that included indicator variables for treatment groups, a history of stroke or TIA, and the interaction between them, and controlled for demographics and clinical characteristics. DOACs were generally ..View full abstract
Awarded by National Heart, Lung and Blood Institute (Bethesda, MD)
Hernandez is funded by the National Heart, Lung and Blood Institute (Bethesda, MD) with grant number K01HL142847.